Policy

Alvotech Lines Up Capital for a Biosimilars IPO

December 9th 2021

By Tony Hagen

Ahead of sales and revenues, Icelandic company Alvotech lines up a massive capital investment and an initial public offering (IPO).

Study: High-risk Population Still in Need of G-CSF Biosimilars

December 8th 2021

By Meir Rinde, MS

The arrival of biosimilars for filgrastim and pegfiltrastim coincided with higher use of granulocyte colony-stimulating factor (G-CSF) for prophylaxis against febrile neutropenia, but many high-risk patients still do not receive the treatment.

Sandoz Reviews Insulin Access, Cost, and Biosimilar Potential

December 7th 2021

By Deana Ferreri, PhD

In a review, Sandoz researchers discuss lingering barriers that prevent insulin prices from falling to more affordable levels.

China Regulators Approve Henlius Bevacizumab Biosimilar Hanbeitai

December 6th 2021

By Tony Hagen

Henlius gains approval in China for Hanbeitai and officials discuss combination therapy options with experimental therapy serplulimab and ophthalmology treatment.

Dr Steven Yates on the 340B Drug Pricing Program

December 5th 2021

Steven Yates, MD, an oncologist and medical director at Intermountain Healthcare, discusses problems underlying the 340B Drug Pricing Program.

Study: Medicare Consolidated Biosimilar Payment Codes Would Save Money

December 2nd 2021

By Meir Rinde, MS

Researchers report findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings.

NJ Court Decision Means 3 Decades of Product Exclusivity for Enbrel

December 1st 2021

By Tony Hagen

In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey has ordered Samsung Bioepis to delay marketing Eticovo until 2029.

Biosimilar Industry Critiques Biden's Drug Pricing Reforms

November 29th 2021

By Tony Hagen

Specialty tiers for biosimilars and reforms that address the proliferation of poor-quality patents would help lower costs and improve access, biosimilar industry veterans said.

Study Models Biosimilar Savings in Ontario From Mandatory Switching

November 24th 2021

By Tony Hagen

Authors of a new study estimated significant savings from biosimilars in Ontario based on deep price discounts and mandatory switching programs.

High Cost, Low Access Still Plague Insulin Market at 100-Year Anniversary

November 23rd 2021

By Deana Ferreri, PhD

Authors of a review discuss barriers to insulin access and potential solutions as the 100-year anniversary of the drug's first use for diabetes gets closer.